

CURRICULUM VITAE

PERSONAL:

Name: Harry A. Drabkin, M.D.

Office Address: Medical University of South Carolina
Hematology/Oncology Division
Fax: 843-792-0644
Phone 843-792-4271
96 Jonathan Lucas Street – 903 CSB
Charleston, SC 29425

Citizenship: United States of America

EDUCATION:

1970 BA Berklee College of Music, Boston, MA
1977 MD University of Kansas School of Medicine, Kansas City, KS

POST-DEGREE TRAINING:

1977 - 1980 Internal Medicine Residency
University of Cincinnati
Cincinnati, Ohio

1980 - 1983 Hematology/Oncology Fellowship
University of Colorado Health Sciences Center
Denver, Colorado

1982 - 1985 Junior Fellow
Eleanor Roosevelt Institute for Cancer Research

SPECIALTY CERTIFICATION:

1980 American Board of Internal Medicine
1983 Board Certified, Medical Oncology

LICENSURE: SC license #AL 30185
SC DHEC 25-30185

ACADEMIC APPOINTMENTS:

1983 – 1985	Instructor Division of Medical Oncology University of Colorado Health Sciences Center Denver, Colorado
1985 – 1991	Assistant Professor Division of Medical Oncology University of Colorado Health Sciences Center Denver, Colorado
1985 – 1998	Institute Fellow Eleanor Roosevelt Institute for Cancer Research
1991 – 1998	Associate Professor Division of Medical Oncology University of Colorado Health Sciences Center Denver, Colorado
1995 – 2007	Director DNA Sequencing Core University of Colorado Cancer Center Denver, Colorado
1998 – 2007	Professor Division of Medical Oncology University of Colorado Health Sciences Center Denver, Colorado
2007 – Present	Gilbreth Professor of Clinical Oncology Division Director Hematology/Oncology Division Department of Medicine Medical University of South Carolina Charleston, South Carolina

MAJOR SCIENTIFIC INTERESTS:

Molecular Biology of Chromosome Alterations in Cancer
Oncogenes and Tumor Suppressor Genes
Developmental Biology and Cancer

CLINICAL ACTIVITIES:

Medical Hematology-Oncology In-Patient Attending, University of Colorado Hospital
Renal Cancer Clinic, Anschutz Cancer Pavilion, University of Colorado Hospital
Consultant – Hereditary Cancer Clinic, Anschutz Cancer Pavilion, University of Colorado Hospital
Medical Hematology-Oncology In-Patient Attending, Medical University of South Carolina, 1 month/year
Renal Cancer Clinic, Hollings Cancer Center, MUSC, 1 clinic day per week

SERVICE:

University of Colorado Health Sciences Center

1991 – 2007	Member, Hematology/Medical Oncology Fellowship Training Program Selection Committee
1995 – 2000	Radiation Safety Committee
1995 – 2007	Director, DNA Sequencing Core, University of Colorado Cancer Center
April 1996	Dean’s Review Committee, School of Pharmacy, for Dr. Carlos Catalano
1996	Dean’s Research Program Development Review Committee, School of Medicine
1998 – Present	Management Committee, Lung Cancer SPORE, University of Colorado Cancer Center
2001 – 2007	Reviewer, Institutional Howard Hughes Awards
2003 – 2007	Co-Director, Hematology/Medical Oncology Fellowship Training Program Selection Committee

Medical University of South Carolina

2007	Molecular and Cellular Biology & Pathobiology Program
2007	Member, HCC Executive Committee
2007	Member, HCC Citizens Advisory Committee
2007	HCC External Scientific Advisory Committee
2007	HCC Advisory Board Committee
2007	HCC Service Line Medical Director Search Committee

National

1990 – Present	Reviewer, National Cancer Institute (Ad Hoc)
1991 – 1997	Member, Western Association of Physicians
1993 – 1998	Member, Human Genome Organization (HUGO)
1994 – 1998	National Institutes of Health, Mammalian Genetics Study Section
2003 – 2006	Member, Mammalian Genetics Study Section, NIH
2003 – Present	Member, SPORE Review Panel
2008-Present	Editorial Board, Cancer Letters

PUBLICATIONS: (141 peer-reviewed manuscripts plus 11 book chapters)

1. **Drabkin HA**, Diaz M, Rowley J, Bradley C and Patterson D: Isolation and analysis of the 21q+ chromosome in the acute myelogenous leukemia 8;21 translocation: Evidence that c-mos is not translocated. Proc Natl Acad Sci USA 82:464-468, 1985.
2. **Drabkin HA**, Bradley C, Hart I, Bleskan J, Li F and Patterson D: Translocation of c-myc in the hereditary renal cell carcinoma associated with a t(3;8) (p 14.2;q24.1) translocation. Proc Natl Acad Sci 82:6980-6984, 1985.
3. Diaz M, Rowley J, LeBeau M, **Drabkin HA** and Patterson D: The role of the c-mos gene in the t(8;21) of human AML. Science 229:767-769, 1985.
4. Patterson D, Van Keuren M, **Drabkin HA**, Watkins P, Gusella J and Scoggin C: Molecular analysis of chromosome 21 using somatic cell hybrids. New York Ann Acad Sci 450:109-120, 1985.
5. Sacchi N, Watson D, Geurts van Kessel Ad HM, Hagameijer A, **Drabkin HA**, Patterson D and Papas TS: Hu-ets-1 and Hu-ets-2 genes are transposed in acute myeloid leukemias with (4;11) and (8;21) translocations. Science 231(4736):379-382, 1986.
6. Van Keuren M, Watkins P, **Drabkin HA**, Jabs Gusella J and Patterson D: Regional localization of DNA sequences on chromosome 21 using somatic cell hybrids. Am J Hum Genet 38:793-804, 1986.
7. Hards RG, Benkovic SJ, Van Keuren ML, Graw SL, **Drabkin HA** and Patterson D: Assignment of a third purine biosynthetic gene (glycinamide ribonucleotide transformylase) to human chromosome 21. Am J Hum Genet 39:179-185, 1986.
8. Van Keuren M, **Drabkin HA**, Hart I, Harker D, Patterson D and Vora S: Regional assignment of human liver-type 6-phosphofructokinase to chromosome 21q22.3 by using somatic cell hybrids and a monoclonal anti-L antibody. Hum Genet 74(1):34-40, 1986.

9. Gerber MJ, Miller Y, **Drabkin HA** and Scoggin CH: Regional assignment of the polymorphic probe D3S3 to 3p14 by molecular hybridization. *Cytogenet Cell Genet* 42:72-74, 1986.
10. Neve RL, Stewart GD, Newcomb P, Van Keuren ML, Patterson D, **Drabkin HA** and Kurnit DM: Human chromosome 21-encoded cDNA clones. *Gene* 49:361-369, 1986.
11. Drayna DT, McLean JW, Wion KL, Trent JM, **Drabkin HA** and Lawn RM: Human apolipoprotein D gene: Gene sequence chromosome location and homology to the alpha-2u-globulin superfamily. *DNA* 6(3):199-204, 1987.
12. Harrison GS, **Drabkin HA**, Kao FT, Hartz J, Hart IM, Chu EHY, Wu BJ and Morimoto RI: Chromosomal location of human genes encoding the major heat shock protein HSP70. *Somatic Cell Molec Genet* 13:119-130, 1987.
13. Mars WM, van Tuinen P, **Drabkin HA**, White JW and Saunders GF: A myeloid-related sequence that localizes to human chromosome 8q21.1-22. *Blood* 71:1713-1719, 1988.
14. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JWM, Collins D, Majoor-Krakauer D, Bonner T, Mathew C, Rubenstein A, Halperin J, McConkie-Rosell A, Green JS, Trotfater JA, Ponder PA, Eierman L, Bowmer MI, Schimke R, Oostra B, Aronin N, Smith DI, **Drabkin HA**, Waziri MH, Hobbs WJ, Martuza RL, Conneally PM, Hsia YE and Gusella JF: Von Hippel Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. *Nature* 332:268-269, 1988.
15. Fisher H, Emrie PA, **Drabkin HA**, Kushnik T, Gerber M, Hofmann T and Jones C: The gene encoding the hydrophobic surfactant protein SP-C is located on 8P and identifies an Eco R-I restriction fragment length polymorphism. *Am J Hum Genet* 43:436-441, 1988.
16. **Drabkin HA**, Kao F-T, Hartz J, Hart I, Gazdar A, Weinberger C, Evans R and Gerber M: Localization of human ERB A2 to chromosome 3p22-24.1 and variable deletion in small cell lung cancer. *Proc Natl Acad Sci* 85(23):9258-9262, 1988.
17. Rao VN, Modi WS, **Drabkin HA**, Patterson D, O'Brien SJ, Papas TS, and Reddy SP: The human erg gene maps to chromosome 21, band q22: Relationship to the 8;21 translocation of acute myelogenous leukemia. *Oncogene* 3(5):497-500, 1988.
18. Sacchi N, Cheng SV, Gusella JF, **Drabkin HA**, Patterson D, Tanzi RE, Haines JH and Papas TS: The ETS genes on chromosome 21 are distal to the breakpoint of the acute myelogenous leukemia translocation (8;21). *Genomics* 3:110-116, 1988.
19. Gerber MJ, **Drabkin HA**, Firnhaber C, Miller Y, Scoggin CH and Smith DI: Regional localization of chromosome 3-specific DNA fragments using a hybrid cell deletion mapping panel. *Am J Hum Genet* 43:442-451, 1988.

20. Gardiner K, Watkins P, Munke M, **Drabkin HA**, Jones C, Kishimoto TK, Springer T and Patterson D: A partial physical map of human chromosome 21. *Somat Cell Mol Genet* 14(6):623-637, 1988.
21. Tantravahl U, Stewart GD, Van Keuren M, McNeil G, Roy S, Patterson D, **Drabkin HA**, Lalande M, Kurnit DM and Latt SA: Isolation of DNA sequences on human chromosome 21 by application of a recombination-based assay to DNA from flow- sorted chromosomes. *Hum Genet* 79(3):196-202, 1988.
22. Gemmill RM, Coyle-Morris J, Ware-Urbe L, Pearson N, Hecht F, Brown RS, Li FP and **Drabkin HA**: A 1.5 megabase restriction map surrounding c-MYC does not include the translocation breakpoint in familial renal cell carcinoma. *Genomics* 4:28-35, 1989.
23. **Drabkin HA**, Sage M, Helms C, Green P, Gemmill R, Smith D, Erickson P, Hart I, Ferguson-Smith A, Ruddle F and Tommerup N: Characterizing the Greig Polysyndactyly 3;7 chromosome translocation t(3;7)(p21.1;p13). *Genomics* 4:518-529, 1989.
24. Smith DI, Mangrulkar R, Geist R, Gilbert J, Kinsman K, **Drabkin HA** and Golembieski W: Saturation of human chromosome 3 with unique sequence hybridization probes. *Genomics* 4(4):453-459, 1989.
25. Smith DI, Golembieski W, **Drabkin HA** and Kiouisis S: Identification of 2 cosmids derived from 3p21.1-p21.2 that contain clusters of rare restriction sites and evolutionarily conserved sequences. *Am J Hum Genet* 45(3):443-447, 1989.
26. Smith DI, Kiouisis S, **Drabkin HA** and Wasmuth J: Isolation and mapping of a polymorphic sequence (3UCI 10) on chromosome 3 [D3S8]. *Nucl Acids Res* 17(14): 5877, 1989.
27. Kiouisis S, **Drabkin HA** and Smith DI: Isolation and mapping of a polymorphic DNA sequence (cA476) on chromosome 3 [D3S94]. *Nucl Acid Res* 17(14):5876, 1989.
28. Miller YE, **Drabkin HA**, Jones C and Fisher JH: Human aminoacylase-1: Cloning, regional assignment to distal chromosome 3p21.1 and identification of a cross- hybridizing sequence on chromosome 18. *Genomics* 8(1):149-154, 1990.
29. **Drabkin HA**, Wright M, Jonsen M, Varkony T, Jones C, Sage M, Gold S and Erickson P: Development of a somatic cell hybrid mapping panel and molecular probes for human chromosome 3. *Genomics* 8(3):435-446, 1990.
30. Weber JL, May PE, Patterson D, **Drabkin HA** and Killary AM: (dC-dA)_n (dG-dT)_n polymorphism Mfd17 on chromosome 3 (D3S196). *Nucl Acid Res* 11:18(13):4038, 1990.

31. Weber JL, Kwitek AE, May PE, Patterson D and **Drabkin HA**: Dinucleotide repeat polymorphisms at the D8S85, D8S87, and D8S88 loci. *Nucl Acid Res* 18(15):4635, 1990.
32. Gao J, Erickson P, Patterson D, Jones C and **Drabkin HA**: Isolation and regional mapping of Not1 and Eag1 libraries from human chromosome 21. *Genomics* 10(1):166-172, 1991.
33. Gemmill R, Varella-Garcia M, Smith DI, Erickson P, Golembieski W, Miller Y, Coyle-Morris J, Tommerup N and **Drabkin HA**: A 2.5 Mb physical map within 3p21.1 spans the breakpoint associated with Greig Cephalopolysyndactyly Syndrome. *Genomics* 11(1):93-102, 1991.
34. Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Chokye PL, Anderson KM, Freiman RN, Klauck SM, Whaley J, Decker H-JH, Hsia YE, Collins D, Halperin J, Lamiell JM, Oostra B, Waziri MH, Gorin MB, Scherer G, **Drabkin HA**, et al: Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease. *Proc Natl Acad Sci* 88:2864-2868, 1991.
35. Gao J, Erickson P, Gardiner K, LeBeau M, Diaz M, Patterson D, Rowley J and **Drabkin HA**: Isolation of a yeast artificial chromosome (YAC) spanning the acute myelogenous leukemia 8;21 translocation breakpoint, t(8;21)(q22;q22.3). *Proc Natl Acad Sci* 88(11):4882-4886, 1991.
36. Smith DI, Liu W, Ginzinger D, Green P, Smith S, Wang N-D, Recchia F, Carolyn K, **Drabkin HA** and Golembieski W: Localization of 616 human chromosome 3-specific cosmids using a somatic cell hybrid deletion mapping panel. *Genomics* 11(1):179-187, 1991.
37. LaForgia S, Morse B, Levy J, Barnea G, Cannizzaro LA, Li F, Nowell PC, Boghosian-Sell L, Glick J, Weston A, Harris CC, **Drabkin HA**, Patterson D, Croce CM, Schlessinger J and Huebner K: Receptor protein-tyrosine phosphatase g is a candidate tumor suppressor gene at human chromosome region 3p21. *Proc Natl Acad Sci* 88:5036-5040, 1991.
38. Barletta C, Druck T, LaForgia S, Calabretta B, **Drabkin HA**, Patterson D, Croce CM and Huebner K: Chromosome locations of the MYB related genes, AMYB and BMYB. *Cancer Res* 51(14):3821-3824, 1991.
39. Gemmill RM and **Drabkin HA**: Report of the second international workshop on chromosome 3. *Cell Genet and Cytogenet* 57(4):162-166, 1991.
40. Morishita K, Parganas E, Willman C, Whittaker M, **Drabkin HA**, Oval J, Taetle R and Ihle JN: Activation of Evi-1 gene expression in human acute myelogenous leukemias by rearrangements spanning 300-400 kb on chromosome 3q26. *Proc Natl Acad Sci USA* 89(9):3937-3941, 1992.

41. **Drabkin HA**, Rabbitts P, Mendez M, Varkony T, Bergh J, Schlessinger J, Erickson P and Gemmill R: Characterization of the submicroscopic deletion in the small-cell lung cancer (SCLC) cell line U2020. *Genes, Chrom Cancer* 5(1):67-74 1992.
42. Wood S, Schertzer M, **Drabkin HA**, Patterson D, Longmire JL and Deaven LL: Characterization of a human chromosome 8 cosmid library constructed from flow- sorted chromosomes. *Cytogenet Cell Genet* 59(4):243-247, 1992.
43. Erickson P, Gao J, Chang K-S, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J and **Drabkin H**. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to drosophila segmentation gene, runt. *Blood* 80(7):1825-1831, 1992.
44. Naylor SL, Sherman S, **Drabkin HA**, Garcis D, Chinn D, DuBois B, Wilkie P, Weber JL, and Nakamura Y: A comprehensive genetic linkage map of the human genome. *Science* 2:258(5079):67-86, 1992.
45. Nucifora G, Birn BJ, Erickson P, Gao J, Le Beau MM, **Drabkin HA** and Rowley JD. Detection of DNA rearrangement in the AML1 and ETO Loci and of an AML1/ETO fusion mRNA in patients with t(8;21) AML. *Blood* 81 (4):883-888, 1993.
46. Jacob CO, Mykytyn K, Varcony T and **Drabkin HA**. Mapping of the interleukin 5 receptor gene to human chromosome 3 p25-p26 and to mouse chromosome 6 close to the raf-1 locus with polymorphic tandem repeat sequences. *Mammalian Genome* 4, 1993.
47. Glesne D, Collart F, Varkony T, **Drabkin HA**, and Huberman E: Chromosomal localization and structure of the human type II IMP dehydrogenase gene. *Genomics* 16(1):274-277, 1993.
48. Chang K-S, Fan Y-H, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P, and **Drabkin HA**. Expression of AML1/ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. *Oncogene* 8(4):983-988, 1993.
49. Downing JR, Head DR, Curcio-Brint AM, Huishof MG, Motroni TA, Raimondi SC, Carroll AJ, **Drabkin HA**, Willman C, Theil KS, Civin CI, and Erickson P: An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. *Blood* 81(11):2860-2865, 1993.
50. Heppel-Parton AC, **Drabkin HA**, et al. The probe BMS1271 identifies a new polymorphic locus (D3S1207) and maps to 3p26-pter. *Cytogenet and Cell Genet* 93(1):64-65, 1993.
51. Pericak-Vance MA, Nunes K, Whisenant E, Loeb D, Small K, Stajich J, Rimmler J, Yamaoka L, Smith D, **Drabkin HA**, and Vance JM. Genetic mapping of dinucleotide

- Repeat polymorphisms and Von Hippel Lindau disease on chromosome 3p25-26. *Am J Hum Genet* 30: 487-491, 1993.
52. Nucifora G, Begy CR, Erickson P, **Drabkin HA** and Rowley JD: The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and EAP, a highly conserved gene associated with Epstein-Barr virus small RNAs. *Proc Natl Acad Sci USA* 90:7784-7788, 1993.
 53. Boldog FL, Gemmill RM, Wilke CM, Glover TW, Nilsson A-S, Chandrasekharappa SC, Brown RS, Li FP and **Drabkin HA**: Positional cloning of the hereditary renal carcinoma 3;8 chromosome translocation breakpoint. *Proc Natl Acad Sci USA* 90:8509-8513, 1993.
 54. Liu W, Piechocki M, Shridhar V, Lyles G, Song Z, Nakamura Y, **Drabkin HA**, Vance J and Smith DI: The isolation of a yeast artificial chromosome (YAC) contig extending for 2 megabases in the vicinity of the Von Hippel Lindau disease gene. *Human Mol Genet* 2:(8)1177-1182, 1993.
 55. Smith SE, Joseph A, Nadeau S, Shridhar V, Gemmill R, **Drabkin HA**, et al: Cloning and characterization of the human t(3;6) (p14;p11) translocation breakpoint associated with Hereditary Hematologic Malignancies. *Cancer. Genet and Cytogenet.* 71(1):15-2129, 1993.
 56. Roche J, Boldog F, Whisenant E, Loeb D, Vance J and **Drabkin HA**. Repeats flanking the hereditary renal carcinoma t(3:8) breakpoint at 3p14.2. *Human Molecular Genetics* 3: 215,1994.
 57. Erickson PF, Robinson M, Owens G and **Drabkin HA**: The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. *Cancer Res* 54:1782-1786, 1994.
 58. Klauck SM, Whisenant E, Wood M, **Drabkin H** and Seizinger BR: Dinucleotide repeat polymorphism at the D3S1255 locus. *Human Molecular Genetics* 3:840, 1994.
 59. Gerken S, Whisenant E, Varkony T, Todd S, Gemmill R, Jones C, Matsunami N, Moore M, Lawrence E, Weissenbach J, White R and **Drabkin H**: Physical and genetic mapping of human chromosome 3 loci containing microsatellite repeats. *Chromosome Research* 2: 4234-427,1994.
 60. Boldog F, Waggoner B, Whisenant E, Schlessinger J, Glover TW, Gemmill R, and **Drabkin HA**: An integrated YAC Contig containing the 3p14.2 hereditary renal carcinoma 3;8 translocation breakpoint and the fragile site, FRA3B. *Genes, Chromosomes and Cancer* 11: 216-221, 1994
 61. Wilke CM, Hall BK, Boldog F, Gemmill RM, Chandrasekharappa SC, **Drabkin HA**, et al: Multicolor FISH mapping of YAC clones in 3p14 and identification of a YAC spanning both

- FRA3B* and the t(3;8) associated with hereditary renal cell carcinoma. *Genomics* 22: 319-326, 1994.
62. George AL, Varkony, TA, **Drabkin H**, Han J, Knoops JF, Finley WH, Brown GB and Haas-Kucherlapati M. Assignment of the Human Heart Tetrodotoxin-Resistant Voltage-Gated Na⁺ Channel alpha-Subunit Gene (*SCN5A*) to 3p21. *Cytogenetics and Cell Genetics*, 68: 67-70 1994
 63. Todd S, Roche J, Hahner L, Bolin R, **Drabkin HA** and Gemmill RM. YAC contigs covering an 8 megabase region of chromosome 3p deleted in the small cell lung cancer cell line U2020. *Genomics* 25: 19-28, 1995.
 64. Leach RJ, Chinn R, Reus BE, Hayes S, Schantz L, Dubois B, Overhauser J, Ballabio A, Callen DF, **Drabkin H**, Lewis TB, Mendgen G and Naylor SL: Regional localization of 188 sequence tagged sites on a somatic cell hybrid mapping panel for human chromosome 3. *Genomics*. 24(3):549-56, 1994
 65. Pekarsky Y, Zabarovsky E, Kashuba V, **Drabkin H**, Rynditch A, Sandberg A and Gardiner K: Cloning of breakpoints in 3q21 associated with hematological malignancy. *Cancer Genet Cytogenet.* 80(1):1-8, 1995.
 66. **Drabkin HA**, Boldog F, Roche J, Todd S, Swanton M, Dessev G, Li S, Waggoner B, Franklin W, Naylor S, Kok K, Buys C and Gemmill R: Tumor suppressor loci from the short arm of chromosome 3. *Lung Cancer* Vol. 11, 153-154,1994.
 67. van den Berg, A., van der Veen, AY, Hulsbeek MMF, Kovacs G, Gemmill RM, **Drabkin HA** and Buys CHCM: Defining the position of the breakpoint of the constitutional t(3;6) in a family with renal cell carcinoma. *Genes, Chromosomes & Cancer* 12:224-228,1995
 68. RM Gemmill, I Chumakov, P Scott, B Waggoner, P Rigault, J Cypser, Q Chen, J Weissenbach, K Gardiner, Y Pekarski, I Le Gall, S Guillon, E Li, L Robinson, L Hahner, S Todd, D Cohen and **HA Drabkin**. An Integrated Yac Contig Map for Human Chromosome 3. *Nature* 377 (6547S): 299-320, 1995
 69. Smith, D.I., Glover, T.W., Gemmill, R., **Drabkin, H**, O'Connell, P. and Naylor, S. Report on the Fifth International Chromosome 3 Workshop. *Cytogenet Cell Genet* 68:125-146, 1995.
 70. Cotter, PD, **Drabkin, HA**, Varkony, T, Smith, DI and Bishop, DE: Assignment of the human housekeeping delta-aminolevulinic synthetase gene (*ALAS1*) to chromosome band 3p21.1 by PCR analysis of somatic cell hybrids. *Cytogenet Cell Genet* 69:207-208 (1995)
 71. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W, Gemmill R and **Drabkin H**. Distinct 3p21.3 deletions in lung cancer,

- analysis of deleted genes and identification of a new human semaphorin. *Oncogene* 12: 1289-1297, 1996
72. Rassool FV, Le Beau MM, Shen M-L, Neilly ME, Ong ST, Boldog F, **Drabkin H** and McKeithan TW. Direct cloning of DNA sequences from the common fragile site at chromosome 3p14.2. *Genomics*. 35(1):109-17, 1996
 73. Sakamoto M. Pinkel D. Mascio L. Sudar D. Peters D. Kuo WL. Yamakawa K. Nakamura Y. **Drabkin H**. Jericevic Z. et al. Semiautomated DNA probe mapping using digital imaging microscopy: II. *Cytometry*. 19(1):60-9, 1995.
 74. Erickson PF, Dessev G, Lasher RS, Philips G, Robinson M and **Drabkin HA**. ETO and AML1 phosphoproteins are co-expressed in hematopoietic cell lines, megakaryocytes and CD34+ progenitors: implications for hematopoiesis and t(8;21) leukemogenesis. *BLOOD* 88:1813-1823, 1996
 75. Song W-J, Van Keuran ML, **Drabkin HA**, Cypser JR, Gemmill RM and Kurnitt DM. Assignment of the Human Slow Skeletal/Cardiac Troponin C (cTnC) Gene to Chromosome 3p14.3-3p21.3. *Cytogen. & Cell Genet.* 75:36-37, 1996
 76. David G, Giuniti P, Abbas N, Couillin P, Stevanin G, Le Paslier D, Weisenbach J, Gemmill R, **Drabkin H**, Harding AE and Brice A. Genetic Refinement and physical mapping of the locus for autosomal dominant cerebellar ataxia with pigmentary macular dystrophy. *Am J. Hum Genet.* 59:1328-1336, 1996
 77. Naylor SL, Carritt B, Boileau C, Beroud C, Alexander c, Allderdice P, Alimov A, Ashworth T, Bonifas J, Bugert P, Buys C, Chipperfield M, Deng G, **Drabkin H** et al. Report of the sixth international workshop on human chromosome 3 mapping 1995. *Cytogenetics Cell Genet* 72: 255-270, 1996
 78. MR Piemontese, E Memeo, M Carella, P Amati, D Bonneau, G Pilia, A Cao, **H Drabkin**, R Gemmill, J Rommens, L Zelante, P Gasparini, L Bisceglia. A YAC contig spanning the blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) and propionic acidemia (PCCB) loci. *European Journal of Human Genetic* 1997, 5, 171-174.
 79. Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Hilliker CE, Hahner L, Anderson M, Weist JS, **Drabkin HA** and Gemmill RM. Homozygous deletions of human chromosome 3p in lung tumors. *Cancer Research* 57: 1344-1352, 1997.
 80. Weist JS, Franklin WA, Otstot JT, Varella-Garcia M, **Drabkin HA**, Gemmill RM, Sidransky D, Saccomanno G, Fountain JW and Anderson MW. Identification of a novel region of homozygous deletion on chromosome 9p in squamous carcinoma of the lung: the location of a putative tumor suppressor gene. *Cancer Research* 57: 1-6, 1997.

81. Boldog, F, Gemmill RM, West J, Robinson M, Robinson L, Li E, Roche J, Todd S, Lundstrom JR, Jacobson J, Klinger H and **Drabkin H** (1997). 3p14 homozygous deletions and sequence analysis of FRA3B. *Human Molecular Genetics* 6: 193-203, 1997.
82. G Paskulin, G Philips, R Morgan, A Sandberg, K Richkind, C Borovik, L McGavran, P Erickson, J Dietz-Band, **H Drabkin** and M Varella-Garcia. Detection of t(8;21) AML1/ETO fusion using fluorescence in situ hybridization: a potential tool for monitoring AML residual disease (1998). *Genes, Chromosome and Cancer* 21:144-151.
83. G. David, N. Abbas. G. Stevanin, A. Dur, G. Yvert, G. Cancel, C. Weber, G. Imbert, F. Saudou, E. Antoniou, **H. Drabkin**, P. Giunti, A. Benomar, M. Ruberg, Y. Agid, J-L Mandel and A. Brice. Cloning of the spinocerebellar ataxia 7 gene (SCA7): highly unstable CAG repeat expansion in ADCA type II. *Nature Genetics* 17: 65-70, 1997.
84. Joëlle Roche, James West, Robert Gemmill et **Harry Drabkin**. Chromosome 3p et recherche de gènes suppresseurs de tumeurs. De nouveaux gènes de Sémaphorines en 3p21.3. *Médecine et Sciences* 14:283-90,1998.
85. Le Beau MM, **Drabkin H**, Glover TW, Gemmill R, Rassool FV, McKeithan TW, Smith DI: A FHIT Tumor Suppressor Gene. *Genes, Chromosomes, Cancer* 21:281-289, 1998
86. Grebe S, Hay I, Wu P, Maciel L, **Drabkin H**, Goellner J, Grant C, Jenkin R and Eberhardt N. Evidence for as yet unidentified tumor suppressor genes on chromosomes 3p and 17p in thyroid cancer. *J.Clin Endocrin Metab.* 82(11): 3684-3691, 1997.
87. H Poirel, V Lacronique, M Mauchauffe, M Le Coniat, E Raffoux, M-T Daniel, P Erickson, **H Drabkin**, R Macleod, HG Drexler, J Ghysdael, R Berger and OA Bernard. Analysis of TEL proteins in human leukemias (1998). *Oncogene* 16: 2895-2903.
88. A Yokomizo, DJ Tindall, **H Drabkin**, R Gemmill, W Franklin, P Yang, K Sugio, DI Smith and Wanguo Liu (1998). PTEN/MMCA1 Mutations in Small Cell Lung Cancers, But Are Not Detected In Non-Small Cell Lung Cancers. *Oncogene* 17:475-479
89. M Varella-Garcia, RM Gemmill, SH Rabenhorst, A Lotto, KP Rao, **HA Drabkin**, JR Murphy and WA Franklin (1998). Chromosomal duplication accompanies allelic loss in non-small cell lung cancer. *Cancer Res.* 15;58(20):4701-7
90. RM Gemmill, JD West, F Boldog, N Tanaka, LJ Robinson, DI Smith, F Li and **HA Drabkin** (1998). The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a novel *patched* related gene, TRC8. *Proc. Natl. Acad. Sci. U.S.A.* 95: 9572-9577.
91. Marileila Varella-Garcia, Françoise Brizard, Joëlle Roche, Georges Flandrin, **Harry Drabkin** and André Brizard. AML1/ETO AND PML/RARA Rearrangements in a Case of AML-M2 with t(15 ;17). *Leukemia and Lymphoma* 33(3-4): 403-406, 1999

92. Hirsch E, Hu LJ, Prigent A, Constantin B, Agid Y, **Drabkin H**, Roche J (1999). Distribution of Semaphorin IV in normal human adult brain and Alzheimer's disease. *Brain Res.* Mar 27;823(1-2):67-79.
93. C. Korch and **H. Drabkin**. Addition of MnCit Improves Accuracy and Facilitates Heterozygosity Detection in DNA Sequencing Reactions Using Fluorescent Dye-Terminators. *Nucleic Acids Res.* 1999 Mar 1;27(5):1405-7.
94. **HA Drabkin**, JD West, M Hotfilder, YM Heng, P Erickson, R Calvo, J Dalmau, RM Gemmill and F Sablitzky (1999). DEF-3(g16/NY-LU-12), An RNA Binding Protein from the 3p21.3 Homozygous Deletion Region in SCLC. *Oncogene* 18: 2589-2597.
95. F de Castro, L Hu, **HA. Drabkin**, C Sotelo and Alain Chédotal. Chemoattraction and Chemorepulsion of olfactory bulb axons by different secreted semaphorins (1999). *J. Neuroscience* 19(11): 4428-4436.
96. C. Korch and **H. Drabkin** (1999). Improved DNA Sequencing Accuracy and Detection of Heterozygous Alleles Using Manganese Citrate and Different Fluorescent Dye Terminators. *Genome Res.* 1999 Jun;9(6):588-95.
97. M Sugita, N Tanaka, S Davidson, S Sekiya, M Varella-Garcia, J West, **HA Drabkin** and RM Gemmill. Molecular definition of an amplification domain within 3q26 in tumors of cervix, ovary and lung. *Cancer Genet Cytogenet.* 2000 Feb;117(1):9-18.
98. Brambilla E., Constantin B., **Drabkin H** and Roche J. (2000). SEMA3F (H.SemaIV) localization in malignant human lung and dividing cells: a suggested role in cell adhesion and cell migration. *Am. J. Path.* 156:939-950.
99. Keith RL, Miller YE, Gemmill RM, **Drabkin HA**, Dempsey EC, Haney J, La Rosa FG, Folkvord J, Kennedy TC, Prindiville S, Franklin WA (2000): Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. *Clin Cancer Res.* 6(5):1616-25.
100. R Calvo, W Franklin, J West, R Rosell, RM Gemmill and **HA Drabkin** (2000). Altered HOX and WNT7a Expression in Human Lung Cancer - *PNAS* 97(23):12776-12781.
101. Calvo R, **Drabkin HA**. Embryonic genes in cancer. *Ann Oncol* 2000;11 Suppl 3:207-18
102. L. Daheron, A. Veinstein, F. Brizard, **H. Drabkin**, L. Lacotte, F. Guilhot, C.J. Larsen, A Brizard and J. Roche (2001). The human LPP gene is fused to MLL in a secondary acute leukemia with a translocation t(3;11) (q28;q23). *Genes chromosome and cancer*, 31: 382-389.

103. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N and **Drabkin HA** (2001). Mutations of β - and γ -catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. *Br J Cancer*. 2001 Jul;85(1):64-8.
104. Tomizawa Y, Sekido Y, Kondo M, Yokota J, Roche R, **Drabkin H**, Lerman MI, Gazdar AF and Minna JD (2001). Inhibition of Lung Cancer Cell Growth and Induction of Apoptosis Following Re-expression of 3p21.3 Tumor Suppressor Gene Candidate SEMA3B *PNAS* 98: 13954–13959.
105. Varella-Garcia M, Hogan CJ, Odom LF, Murata-Collins JL, Ai H, Chen L, Richkind K, Paskulin G, Andreeff M, Brizard A, McGavran L, Gemmill RM, Berger R, **Drabkin HA**. Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. *Leukemia* 2001 Sep;15(9):1408-1414.
106. RM Bremnes, R Veve, E Gabrielson, FR Hirsch, A Baron, L Bemis, RM Gemmill, **HA Drabkin** and WA Franklin (2001). High Throughput Tissue Microarray Analysis Used to Evaluate the Prognostic Role of the E-cadherin Pathway in Non-Small Cell Lung Cancer. *J Clin Oncol*. 2002 May 15;20(10):2417-28.
107. Joëlle Roche and **Harry A. Drabkin** (2001). The Role Of Semaphorins in Lung Cancer. *Clinical Lung Cancer*. 3 (2):145-150.
108. **HA Drabkin**, C Parsy, K Ferguson, F Guilhot, L Lacotte, L Roy, C Zeng, A Baron, SP Hunger, M Varella-Garcia, R Gemmill, F Brizard, A Brizard and Joëlle Roche. Quantitative Hox Expression In Chromosomally Defined Subsets Of Acute Myelogenous Leukemia. *Leukemia* (2002) 16, 186–195.
109. RM Gemmill, LT Bemis, JP Lee, MA Sozen, A Baron, C Zeng, PF Erickson, JE Hooper and **HA Drabkin** (2002). The TRC8 Hereditary Kidney Cancer Gene Suppresses Growth and Functions with VHL in a Common Pathway. *Oncogene*. 2002 May 16;21(22):3507-16.
110. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, **Drabkin H**, Hiebert SW, Klug CA (2002). Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. *Mol Cell Biol* 22(15):5506-17.
111. P Nasarre, B Constantin, L Rouhaud, V Castellani, G Raymond, **HA Drabkin** and J Roche (2003). Semaphorin SEMA3F Inhibits Cell Attachment and Spreading and Induces Cell Death in Human Mammary Tumor Cells. *Neoplasia* 5(1):83-92.
112. S. Lantuejoul, B. Constantin, **H. Drabkin**, C. Brambilla, J. Roche and E. Brambilla (2003). VEGF, Semaphorin SEMA3F and their common receptors neuropilins NP1 and NP2 expressions in preinvasive bronchial lesions and lung tumors. *J Pathol*. 200(3):336-47

113. S. Kusy, L. Funkelstein, D. Bourgeois, **H. Drabkin**, G. Rougon, J. Roche and V. Castellani (2003). Redundant functions but temporal and regional regulation of two alternatively-spliced isoforms of Semaphorin 3F in the nervous system. *Molecular and Cellular Neurosciences* 24:409-418.
114. Puig-Kröger, T. Sánchez-Elsner, N. Ruiz, E.J. Andreu, F. Prosper, U.B. Jensen, J. Gil, P. Erickson, **H. Drabkin**, Y. Groner and A.L. Corbí (2003). RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. *Blood*. 2003 Nov 1;102(9):3252-61.
115. T Ohira, RM Gemmill, L Bemis, P Erickson, K Ferguson, S Kusy, J Roche, E Brambilla, C Zeng, A Baron, E Wilder, A Rustgi, J Kitajewski, E Gabrielson, R Bremnes, W Franklin and **HA Drabkin** (2003). WNT7a induces E-cadherin in lung cancer cells (2003). *PNAS* 100(18):10429-34.
116. J Roche, C Zeng, A Baron, S Gadgil, RM Gemmill, I Tigaud, X Thomas and **HA Drabkin** (2004). HOX Expression in AML Identifies A Distinct Subset Of Patients With Intermediate Cytogenetics. *Leukemia*. Jun;18(6):1059-63.
117. Salon C, Moro D, Lantuejoul S, Brichon Py P, **Drabkin H**, Brambilla C, Brambilla E (2004). E-cadherin-beta-catenin adhesion complex in neuroendocrine tumors of the lung: a suggested role upon local invasion and metastasis. *Hum Pathol*. 2004 Sep;35(9):1148-55.
118. RM Gemmill, J Lee, D Chamovitz, D Segal, JE Hooper and **HA Drabkin** (2005). Growth Suppression Induced by the TRC8 Hereditary Renal Cell Cancer Gene is Dependent upon JAB1/CSN5. *Oncogene*. 24(21):3503-11.
119. P. Nasarre, S. Kusy, B. Constantin, V. Castellani, **H. Drabkin**, D. Bagnard & J. Roche (2005). Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. *Neoplasia*. Feb;7(2):180-9.
120. Kusy S, Nasarre P, Chan D, Potiron V, Constantin B, Gemmill R, **Drabkin H** & Roche J (2005). Selective Suppression of *In Vivo* Tumorigenicity by Semaphorin SEMA3F in Lung Cancer Cells. *Neoplasia* May;7(5):457-65.
121. P. Nasarre, B. Constantin, **HA Drabkin** et J. Roche (2005). Sémaphorines et cancers : état des lieux. *Médecine et Sciences*; 21 : 641-7
122. RM Gemmill, M Zhou, C Korch, RM Bukowski and **HA Drabkin** (2005). Synergistic Growth Inhibition by Iressa and Rapamycin Is Modulated by VHL Mutations in Renal Cell Carcinoma. *British Journal of Cancer*. 2005 Jun 20;92(12):2266-77.

123. S Kusy, V Potiron, C Zeng, W Franklin, E Brambilla, J Minna, **HA Drabkin** & J Roche (2005). Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. *Biochim Biophys Acta.* 1730(1):66-76.
124. XY Su, **H Drabkin**, E Clappier, E Morgado, M Busson, S Romana, J Soulier, R Berger, OA Bernar and C Lavau (2006). Comparative Analysis of the Leukemogenic Potential of HOXA13 to other Human T-Cell Acute Lymphoblastic Leukemia Associated Homeobox Oncogenes. *Genes, Chromosomes and Cancer*, Sep;45(9):846-55
125. S Witta, R Gemmill, F Hirsch, C Coldren, K Hedman, B Helfrich, L Ravdel, R Dziadziuszko, D Chan, Z Chan, A Baron, W Franklin, **H Drabkin**, L Girard, A Gazdar, J Minna & P Bunn (2006). Restoring E-cadherin Expression Increases Sensitivity to EGFR Inhibitors in Lung Cancer Cell Lines. *Cancer Res.* Jan 15;66(2):944-50.
126. M Dohadwala, SC Yang, J Luo, S Sharma, RK Batra, M Huang, Y Lin, L Goodglick, K Krysan, MC Fishbein, L Hong, R Cameron, RM Gemmill, **HA Drabkin** and SM Dubinett (2006). Cyclooxygenase-2-dependent regulation of E-cadherin expression: PGE2 induces E-cadherin transcriptional repressors ZEB1 and Snail in NSCLC. *Cancer Res.* May 15;66(10):5338-45.
127. Clarhaut J, Roche J & **Drabkin H** (2006). Semaphorins in Lung Cancer. *J. Thoracic Oncology* (1) No. 3, March 2006 pp1-2.
128. A C G Xavier, C Marshall, F G La Rosa, LJ Costa & **H Drabkin** (2006). Woman With a Papillary Pulmonary Lesion and a Complex Renal Cyst. *Oncology (Williston Park)*. 2006 Oct;20(11):1437-9, 1443.
129. A Brauweiler, K Lorick, JP Lee, D Chan, A Weissman, **HA Drabkin** and RM Gemmill (2006). RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene. *Oncogene* – 2007 Apr 5;26(16):2263-71.
130. LJ Costa, RM Gemmill & **HA Drabkin** (2007), Upstream signaling inhibition enhances the Rapamycin effect on growth of Kidney Cancer Cells. *Urology*. 2007 Mar;69(3):596-602.
131. CW Ryan, BH Goldman, PN Lara, Jr, PC Mack, TM Beer, CM Tangen **HA Drabkin**, ED Crawford (2007). Sorafenib with Interferon alpha-2b as First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. *J Clin Oncol.* Aug 1;25(22):3296-301.
132. RM Bukowski, FF Kabbinavar, RA Figlin, K Flaherty, S Srinivas, U Vaishampayan, **H Drabkin**, J Dutcher, S Ryba, Q Xia, FA Scappaticci, and D McDermott (2007). Randomized Phase II Study of Erlotinib Combined with Bevacizumab Compared with Bevacizumab Alone in Metastatic Renal Cancer. *J Clin Oncol.* 2007 Oct 10;25(29):4536-41.

133. VA Potiron, P Nasarre, JA Clarhaut, GH Augustin, RM Gemmill, J Roche and **HA Drabkin** (2007). Semaphorin SEMA3F Inhibits ILK-AKT-STAT3 and ERK-1/2 Signaling in H157 Lung Cancer Cells. *Cancer Res.* 2007 Sep 15;67(18):8708-15.
134. Poland KS, Azim M, Folsom M, Goldfarb R, Naeem R, Korch C, **Drabkin HA**, Gemmill RM, Plon SE. A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. *Genes Chromosomes Cancer.* 2007 Sep;46(9):805-12.
135. A Ballonoff, B Kavanagh, R Nash, **H Drabkin**, J Trotter, R Rabinovitch (2007). Hodgkin Lymphoma-Related Vanishing Bile Duct Syndrome and Idiopathic Cholestasis, Recovery of Liver Function with Eradication of Lymphoma: A Case Report and Review of the World's Literature. *Acta Oncol.* 2007 Sep 28;:1-9.
136. LJ Costa & **HA Drabkin** (2007). Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies. *The Oncologist.* Dec;12(12):1404-15.
137. Potiron VA, **Drabkin HA**, Roche J. SEMA3F (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F). *Atlas Genet Cytogenet Oncol Haematol.* March 2008. URL: <http://AtlasGeneticsOncology.org/Genes/SEMA3FID42254ch3p21.html>
138. M Andreeff, V Ruvolo, S Gadgil, C Zeng, K Coombes, W Chen, S Kornblau, AE Barón & **HA Drabkin** (2008). HOX Expression Patterns Across Major Acute Myelogenous Leukemia Cytogenetic Groups and Identification of a Common Signature for Favorable AML – Leukemia, 2008 Nov;22(11):2041-7.
139. Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America (2008). WM Stadler, RA Figlin, DF McDermott, JP Dutcher, JJ Knox, WH Miller, JD Hainsworth, CA Henderson, JR George, J Hajdenberg, TL Kindwall-Keller, MS Ernstoff, **HA Drabkin** et al., Submitted
140. J Clarhaut, RM. Gemmill, S Ait-Si-Ali, J Imbert, **HA Drabkin** and J Roche (2009). Semaphorin SEMA3F tumor suppressor gene is repressed by ZEB-1 in lung cancer cells. *Neoplasia.* 2009 Feb;11(2):157-66
141. VA Potiron, J Roche and **HA Drabkin** (2009). Semaphorins and their receptors in lung cancer. *Cancer Letters* 273 (2009) 1–14.
142. JP Lee, **HA Drabkin**, A Brauweiler, L Costa, K Lorick, M Zhou, M Rudolph, R Bukowski, AM Weissman and RM Gemmill (2009). TRC8 is a Sterol-Regulated E3 Ubiquitin Ligase that Destablizes INSIG and SREBP (*tentatively accepted pending revision*).
143. Sergej Konoplev, Xuelin Huang, **Harry A. Drabkin**, Hartmut Koeppen, Dan Jones, Hagop M. Kantarjian, Guillermo Garcia-Manero, Weina Chen, L. Jeffrey Medeiros, Carlos E.

Bueso-Ramos (2009). Immunohistochemical Assessment of Nucleophosmin Expression in Bone Marrow of Acute Myeloid Leukemia Patients is Not Predictive of Prognosis. (Cancer – *in press*).

144. J Starkova and **H Drabkin** (2009). PKC412 treatment of leukemic cells reveals a novel interaction between FLT3 kinase and DLX1/2 (*tentatively accepted pending revision*).

BOOK CHAPTERS AND REVIEWS:

1. **Drabkin HA**: The molecular biology of chromosome alterations in myelogenous leukemia. West J Med 143(6):825-828, 1985.
2. **Drabkin HA**, Van Keuren M, Hart I, Duesberg P, Sacchi N, Papas T and Patterson D: Precise localization of the Hu-ets-2 gene in the critical region of chromosome 21 in t(8;21). AML and Down's syndrome. In Advances in Gene Technology: Molecular Biology of the Endocrine System. Puett D, Ahmad F, Black S, Lopez DM, Meener MH, Scott WA, Whelan WY (eds), Cambridge University Press, England, pp. 112-113, 1986.
3. **Drabkin HA**, Smith D, Jones C, Jonsen M, Sage M, Gold S, Glover T, Dobrovic A, Bradley WEC and Gemmill R: Regional and physical mapping studies involving rearrangements of human chromosome 3. In: Cancer Cells/7: Molecular Diagnostics of Human Cancer. Furth M and Greaves M (eds). Cold Spring Harbor Press, pp 63-68, 1989.
4. **Drabkin HA** and Miller YE: Molecular mechanisms of malignancy. In Diseases of the Kidney, 5th Ed., Little, Brown and Co., Boston, pp. 777-784, 1992.
5. Mendez M, Erickson P, Scott P, **Drabkin HA** and Gemmill RM. Isolation of YAC Clones from Genomic Libraries by Southern Blot Hybridization. YAC libraries; A user's guide. Dr. David Nelson (ed). W.H. Freeman and Co., NY, 1993.
6. **Drabkin, HA** and Erickson, P. Down Syndrome and Leukemia, an Update. in Etiology and Pathogenesis of Down Syndrome. Progress in Clinical and Biological Research. Vol 393:169-174, 1995, Epstein, CJ et al., *Editor*, Wiley-Liss
7. **Drabkin HA** and Miller YE: Molecular mechanisms of malignancy. In Diseases of the Kidney, 5th Ed., Little, Brown and Co., Boston, 1997
8. Gemmill RM and **Drabkin HA**: Chromosome 3p Loss in Lung Cancer. In: Biology of Lung Cancer, Kane/Bunn (ed), Marcel Decker, Inc. , pp. 465-502, 1998
9. **Drabkin HA** and Gemmill, RM. Molecular Mechanisms of Renal Cancer. In Diseases of the Kidney, 6th Ed., Little, Brown and Co., Boston, 2001.

10. J. Roche, **H. Drabkin** and E. Brambilla. Neuropilin and its Ligands in Normal Lung and Cancer (2002). Chapter 10, Neuropilin: From Nervous System to Vascular. Editor: Dominique Bagnard. ISBN: 0-306-47416-6. <http://www.eurekah.com/>
11. RM Gemmill, L Costa, B Medeiros and **HA Drabkin** (2005). Molecular Pathogenesis of Renal Cancer and Related Treatment Aspects. Diseases of the Kidney, 6th Ed., R. Schrier, Editor, Little, Brown and Co., Boston.

ABSTRACTS AND PRESENTATIONS (141):

1. **Drabkin HA**, Robinson A and Seligman PA: Philadelphia (Ph') chromosome positive acute myelogenous leukemia. Blood 60(5) Suppl.1: 423, 1982.
2. **Drabkin HA**, Bleskan J and Patterson D: Poster presented FASEB Summer Research Conference July, "Cloning of Genes from Chromosome 8", 1983.
3. **Drabkin HA**, Diaz M, Bradley M, LeBeau MM, Rowley JD and Patterson D: Analysis of the acute myelogenous leukemia (AML) 8;21 translocation. Presented, RNA Tumor Viruses in Human Cancer International Research Conference, Denver, Colorado, June 10-14, 1984.
4. Van Keuren M, **Drabkin HA**, Patterson D, Diaz M, Rowley J, Watkins P and Gusella J: Poster presented FEBS Winter School - The Biochemistry of Aging, "Mapping of Chromosome 21-specific DNA sequences and the use of a repetitive sequence for fine-structure mapping." 1984.
5. **Drabkin HA**, Diaz M, Bradley CM, LeBeau MM, Rowley JD, Trujillo J, Cork C and Patterson D: Analysis of the acute myelogenous leukemia (AML) 8;21 translocation. Blood Vol. 64, No. 5, Supplement 1, pg 201a, 1984.
6. Van Keuren M, **Drabkin HA**, Patterson D, Diaz M, Rowley J, Watkins P and Gusella J: Regional mapping of DNA sequences from chromosome 21 and the use of repetitive sequence for fine-structure mapping. Presented, 17th Annual Birth Defects Conference, University of Colorado, Denver, June 11-17, 1984.
7. **Drabkin HA**, Bradley C, Li F and Patterson D: Analysis of the hereditary renal cell carcinoma 3;8 translocation. Evidence that c-myc is translocated. Clin Res 33(1):41A, 1985.
8. **Drabkin HA**, Bradley C, Hart I, Li F and Patterson D: Analysis of the hereditary renal cell carcinoma 3;8 translocation: Evidence that c-myc is translocated. Proc of the Amer Assn for Cancer Res, #272, 1985.

9. Van Keuren M, **Drabkin HA**, Watkins P, Gusella J and Patterson D: Regional mapping of DNA sequences to chromosome 21. Eighth Human Gene Mapping Workshop, Helsinki, Finland, August 4-10, Cytology and Cell Genetics, 1985.
10. Van Keuren M, **Drabkin HA**, Hart I, Patterson D and Vora S: Regional mapping of liver-type 6-phosphofructokinase to 21q22.3. *Am J of Hum Genet* 37:A20, 1985.
11. **Drabkin HA**, Bradley C, Hart I, Bleskan J, Li F and Patterson D: Translocation of c-myc in the hereditary renal cell carcinoma associated with a t(3;8)(p14.2;q24.13) chromosomal translocation. Presented at Genetics of Development International Symposium, Toronto, Canada, Sept. 29-Oct. 3, 1985.
12. **Drabkin HA**, Van Keuren M, Sacchi N, Papas T and Patterson D: Localization of the chromosome 21 Hu-ets-2 gene and translocation in t(8;21) AML. *J Cell Biochem Suppl* 10A:36A:18, 1986.
13. Harrison GS, Morimoto R, Kao F-T, Chu EHY, Wu SJ and **Drabkin HA**: Chromosomal location of human genes encoding the major heat shock protein HSP70. *Am J Hum Genet* 39:464, 1986.
14. **Drabkin HA**, LeBeau MM, Rowley JD, Glode LM, Carrino J and Diaz MO: Isolation and analysis of the acute myelogenous leukemia (AML) 3;3 translocation. *Proc AACR* 28:202, 1987.
15. Harrison GS, DiBella NJ, Kao F-T and **Drabkin HA**: Chromosomal location of human genes encoding the major heat shock protein HSP70. *Proc AACR* 28:201, 1987.
16. **Drabkin HA**, Gemmill R and Smith D: Approach towards a physical map of chromosome 3p regions involved in malignant and developmental disease. Presented at M.D. Anderson 40th Annual Symposium on Fundamental Cancer. November, Houston, TX. 1987.
17. **Drabkin HA**, Kao F-T, Weinberger C and Evans R: Human c-erbA is located at chromosome 3p21.33-p22. *Am J Hum Genet* 41(3):A25, 1987.
18. Golembieski W, Gilbert JD, Hu Y, McIntyre M, **Drabkin HA** and Smith D: Progress in the physical dissection of human chromosome 3. *Am J Hum Genet* 41(3):A167, 1987.
19. Gemmill RM, Coyle-Morris J, Ware-Urbe L, **Drabkin HA**, Brown RS and Hecht F: 1500 kb pulsed field gel map surrounding myc does not include the translocation in familial renal cell carcinoma. *Am J Hum Genet* 41(3):A215, 1987.
20. McIntyre M, Smith D and **Drabkin HA**: Regional localization of chromosome 3 specific cosmids containing clusters of rare restriction sites. *Am J Hum Genet* 41(3):A178, 1987.

21. Harrison G, Marcell T, Hart I and **Drabkin HA**: Examination of the putative suppressor function on human chromosome 3. *Am J Hum Genet* 41(3): A169, 1987.
22. Wood S, Mawji N, Schertzer M, Tak B, Patterson D and **Drabkin HA**: Regional mapping of DNA sequences on human chromosome 8. *Am J Hum Genet* 41(3): A192, 1987.
23. Sage M, Hart I, Green P, Tommerup N and **Drabkin HA**: Isolation and analysis of the Greig polysyndactyly-craniofacial anomalies syndrome 3;7 translocation. *Am J Hum Genet* 41(3):A106, 1987.
24. Smith D and **Drabkin HA**: Regional localization of chromosome 3-specific cosmids containing clusters of rare restriction sites using a hybrid cell deletion mapping panel. *Am J Hum Genet* 41(3):A178, 1987.
25. Gemmill RM, Smith DI and **Drabkin HA**: Physical mapping within human chromosomal region 3p14 to p21. Cold Spring Harbor Laboratory Meeting: Genome Mapping and Sequencing, April, 1987.
26. Gerber MJ, Scoggin CH, Weinberger C, Evans RM and **Drabkin HA**: Loss of oncogene c-erb-A heterozygosity in small cell lung cancer. *Clin Res* 36(1):170, 1988.
27. **Drabkin HA**, Smith D, Jones C and Gemmill R: Towards a physical map of human chromosome 3 and molecular analysis of disease related rearrangements. Cold Spring Harbor Laboratory Meeting: The Molecular Diagnostics of Human Cancer, September, 1988.
28. Stewart GD, Tanzi RE, Kishimoto TK, Buraczynska M, Haines JL, **Drabkin HA**, Gusella JF, Springer TA, Kurnit DM and Van Keuren M: The CD18 gene maps to distal chromosome 21q22.3: RFLPs create a highly informative terminal haplotype. *Am Hum Genet* 43(3):A160, 1988.
29. Jonsen M, Erickson P, Gemmill R, Jones C, Gold S, Baskin J, Sage M and **Drabkin HA**: Physical mapping studies of human chromosome. UCLA Symposium, 3:89, 1988.
30. **Drabkin HA**, Erickson P, Jones C, Jonsen M, Varcony T, Baskin J, Gao J, Wright M, Gold S, Smith D and Gemmill R: Progress toward a physical map and analysis of specific rearrangements involving human chromosome 3. Cold Spring Harbor Laboratory Meeting: Genome Mapping, April, 1989.
31. Gao J, Erickson P, Patterson D and **Drabkin HA**: Physical localization of Not1 and Eag1 boundary clones on chromosome 21. Human Genome I, San Diego, CA, October 2-4, 1989 (presented).

32. Jonsen M, Erickson P, Varkony T, Wright M, Jones C and **Drabkin HA**: Progress toward the development of physical map of human chromosome 3. Human Genome I, San Diego, CA, October 2-4, 1989 (presented).
33. Smith D, Kiouisis S, Lalley P, **Drabkin HA**, Smith S and Golembieski W: Gene map of human chromosome 3 and corresponding mouse map. Human Genet 45(4):A162, 1989.
34. Miller YE, **Drabkin HA**, Jones C and Fisher JH: Aminoacylase-1: cDNA isolation, regional assignment to chromosome 3p21.1 and identification of a cross-hybridizing sequence on chromosome 18. Human Genet 45(4):A28, 1989.
35. Kiouisis S, **Drabkin HA**, Seizinger B and Smith D: Nine cosmids derived from 3p14.1- pter that identify restriction fragment length polymorphisms: Human Genet 45(4):A146, 1989.
36. Seizinger BR, Farmer G, Haines J, Anderson K, Whaley J, Hettlich C, Decker J, Rouleau G, Smith D, **Drabkin HA**, Filling-Katz M, Neumann H, Collins D, Hsia E, Green J, Waziri M, Gusella J and Li F: Isolating the gene(s) for von Hippel-Lindau disease and renal cell carcinoma. Human Genet 45(4):A32, 1989.
37. Wood ME, Jones C and **Drabkin HA**: Co-localization of the chromosome 3 genes; thyroid hormone receptor (THRB), retinoic acid receptor (RARβ) and the raf oncogene (RAF1) to 3p24.2>3p25. Am J of Hum Genet 47(3):1046, 1990.
38. **Drabkin HA**, Gao J, Patterson D, Jones C and Erickson P: Isolation and regional mapping of Not1 and Eag1 libraries from human chromosome 21. Am J of Hum Genet 47(3):0979, 1990.
39. Klauck SM, Menon A, Whaley JM, Smith DI, **Drabkin HA** and Seizinger BR: Identification of highly polymorphic (CA)_n repeat blocks in the vicinity of the Von Hippel Lindau Gene on chromosome 3p. Am J of Hum Genet 47(3):0728, 1990.
40. Wang N, Smith S, Lui W, **Drabkin HA** and Smith D: Molecular analysis of the constitutive fragile site mapping at 3p14.2. Am J of Hum Genet 47(3):0082, 1990.
41. Golembieski W, Smith S, Recchia F, **Drabkin HA**, Buchhagen D, Minna J and Smith D: Isolation and localization of large numbers of chromosome 3 specific cosmids that contain clusters of rare restriction endonuclease sites and transcribed sequences. Am J of Hum Genet 47(3):0991, 1990.
42. Smith S, Golembieski W, Lui W, Gemmill R, **Drabkin HA** and Smith D: Progress in the cloning of the 3;7 translocation breakpoint associated with greig polysyndactyly syndrome. Am J of Hum Genet 47(3):1032, 1990.

43. Seizinger BR, Smith D, Klauck SM, Whaley JM, Filling-Katz M, Neumann H, Anderson K, Freiman R, Decker J, Green J, Hsia E, Halperin J, Waziri M, Collins D, Drabkin HA and Haines J: Toward the isolation of the gene causing Von Hippel Lindau disease: Identification of tightly linked flanking markers. *Am J Hum Genet* 47(3):0059, 1990.
44. Gemmill B, Erickson P, Smith D, Miller Y, Tommerup N and Drabkin HA: A chromosome 3 map which identifies the greig cephalopolysyndactyly translocation breakpoint. Submitted to Human Genome II, 1990.
45. Gao J, Erickson P, Gardiner K, LeBeau M, Diaz M, Patterson D, Rowley J and Drabkin HA: Isolation of a yeast artificial chromosome (YAC) spanning the acute myelogenous leukemia 8;21 translocation breakpoint, t(8;21)(q22;q22.3). *Keystone Symposia*, 1991.
46. Smith DI, Golembieski W, Smith S, Shridhar V, Ginzinger D, Recchia F, Billotto R, Merchant K, Phillips N, Drabkin HA and Miller OJ: Characterization of human chromosomal band 3p21 and the search for genes. Presented at Cold Spring Harbor, 1991.
47. Erickson PF, Gao J, Wood ME, LeBeau MM, Diaz MO, Rowley JD and Drabkin HA: Molecular cloning of chromosome 8 material at the t(8;21)(q22;q22.3) breakpoint in acute myelogenous leukemia. Presented at the 33rd Annual Meeting of the American Society of Hematology, 1991.
48. Smith DI, Golembieski W, Recchia F, Billotto R, Ginzinger D and Drabkin HA: Isolation of a significant proportion of human chromosome 3 sequences present within 7,000 recombinant clones. 8th International Congress of Human Genetics, 1991.
49. Shridhar V, Golembieski W, Drabkin HA, Miller OJ and Smith DI: Cluster cosmids and Not1 boundary clones contain two new genes within human chromosomal band 3p21.1. 8th International Congress of Human Genetics, 1991.
50. Van Hul W, Van Camp G, Stuyver L, Erickson P, Gao J, Drabkin HA and Van Broeckhoven C: Physical mapping of the proximal region of chromosome 21q in relation to familial Alzheimer's Disease. *Human Gene Mapping* 11, 1991.
51. Drabkin HA and Gemmill RM: YAC isolation and contig assembly for human chromosome 3. International Human Chromosome 3 Workshop, Tokyo, March, 1992.
52. Drabkin HA and Gemmill RM: YAC isolation and contig assembly for human chromosome 3. Cold Spring Harbor Genome Mapping & Sequencing, Cold Spring Harbor, NY, May 6-10, 1992.
53. Drabkin HA, Whisenant E, Jones MR, Nakamura Y, Yamaoka L, Nunes K, Loeb D, Stajich J, Rimmler J and Perichak-Vance MA: Genetic mapping of dinucleotide repeat

- polymorphisms and Von Hippel Lindau disease on chromosome 3p25-26. American Society of Human Genetics, 1992.
54. Nucifora G, Birn DJ, Erickson P, Gao J, LeBeau MM, **Drabkin HA**, and Rowley JD: AML1/ETO Fusion mRNA Detected by Polymerase Chain Reaction in AML Patients with the t(8:21) at Diagnosis, in Relapse and in Remission. *Molecular Oncology-III. Mechanisms of Oncogenesis*, pg. 355a, 1992.
 55. Liu W, Piechocki M, Shridhar V, Tchopcev N, Lyles G, **Drabkin HA**, Nakamura Y, and Smith DI. Isolation of the Region Surrounding the Von Hippel Lindau Disease Gene Within Overlapping Yeast Artificial Chromosomes. *Am J Hum Genet* 51(4):A52, 1992.
 56. Naylor SL, Garcia D, Chinn R, Dubois B, Huang WH, Mengden GA, Sherman S, Hudson T, Dracopoli N, **Drabkin HA**, Wilkie P, and Weber J: Map Construction for Human Chromosome 3. *Am J Hum Genet* 51(4):A197, 1992.
 57. Vance JM, **Drabkin HA**, Whisenant E, Jones MA, Nakamura Y, Yamaoka L, Nunes K, Loeb D, Smith D, Stajich J, Rimmler J, and Pericak-Vance MA: Genetic mapping of dinucleotide repeat polymorphisms and Von Hippel Lindau disease on chromosome 3p25-26. *Am J Hum Genet* 51(4):A198, 1992.
 58. Boldog F, Gemmill R, Nilsson A-S, Glover T, Wilkie C and **Drabkin HA**: A 3-Mb YAC Contig and Isolation of a Candidate 3P Tumor Suppressor Gene from the Renal Carcinoma 3;8 Translocation Breakpoint. Cold Spring Harbor Laboratory, May 12-16, 1993.
 59. Boldog F, Gemmill R, Nilsson A-S, Glover T, Wilkie C and **Drabkin HA**: A 3-Mb YAC Contig and Isolation of a Candidate 3P Tumor Suppressor Gene from the Renal Carcinoma 3;8 Translocation Breakpoint. 4th International Chromosome 3 Workshop, University of Groningen, Groningen, The Netherlands, May 13-15, 1993
 60. Scott P, **Drabkin HA** and Gemmill R: Chromosome 3 Image Database: A Program for Image and Text Data Retrieval for Chromosome Mapping. Cold Spring Harbor Laboratory, May 12-16, 1993.
 61. Wilke C, Chandrasekharappa BHS and Glover TW: Departments of Pediatrics and Human Genetic, University of Michigan, Ann Arbor, Ferenc Boldog, Robert Gemmill, and **Harry Drabkin**. Ordering of YAC contigs within 3p14 by FISH analysis. Human Chromosome 3 Workshop, The Netherlands, 1993.
 62. Maciel LMZ, Wu P, Hay ID, Stelter A, Jenkins RB, **Drabkin HA** and Eberhardt NA: Follicular Thyroid Carcinoma Associated with Loss of Heterozygosity on Chromosome 3p as Revealed by CA Dinucleotide Repeat Mapping. The American Thyroid Association, 1993.

63. Boldog FA, Gemmill R, Wilke CM, Glover TW, Nilsson A-S, Chandrasekharappa SC, Brown RS, Li FP and **Drabkin HA**: Positional cloning of the hereditary renal carcinoma 3;8 chromosome translocation breakpoint. American Society of Human Genetics, 1993.
64. Boldog FA, Gemmill R, Wilke CM, Glover TW, Nilsson A-S, Chandrasekharappa SC, Brown RS, Li FP and **Drabkin HA**: Positional cloning of the hereditary renal carcinoma 3;8 chromosome translocation breakpoint. 43rd Annual Meeting of the American Society of Human Genetics, New Orleans, LA, October 5-9, 1993.
65. **Drabkin HA**, Robinson M, Owens G, and Erickson PF. DNA sequence analysis suggests the ETO portion of AML t(8;21) fusion transcript encodes a transcriptional transactivating domain. American Society of Human Genetics, 1993.
66. Smith SE, Joseph A, Shridhar R, Knuutila S, **Drabkin HA**, Shridhar V, Gemmill R and Smith DI. The molecular cloning of the 5(3;6)(p14.3;p11) chromosomal translocation associated with hematologic malignancies identifies several genes in the vicinity of the breakpoint. 43rd Annual Meeting of the American Society of Human Genetics, New Orleans, LA, October 5-9; Am. J. Hum. Genet., 53:173, 1993.
67. Glesne D, Collart F, Varkony T, **Drabkin HA**, and Huberman E: Chromosomal localization and structure of the human type II IMP dehydrogenase gene. Proc Annu Meet Am Assoc Cancer Res 34:A2956, 1993.
68. Nucifora G, Birn DJ, Espinosa R III, Erickson P, LeBeau M, Roulston D, **Drabkin HA**, and RowleyJD: Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Proc Annu Meet Am Assoc Cancer Res 34:A2966, 1993.
69. Wilke CM, Hall B, Gemmill R, Boldog F, **Drabkin H**, Chandrasekaharappa S, Abel K and Glover TW, Isolation and characterization of YAC and phage clones spanning the 3p14.2 fragile site (FRA3B). 43rd Annual Meeting of the American Society of Human Genetics, New Orleans, LA, October 5-9; Am J Hum Genet, 53:239, 1993.
70. **Drabkin HA**, Boldog F, Roche J, Todd S, Swanton M, Dessev G, Li S, Waggoner B, Franklin W, Naylor S, Kok K, Buys C and Gemmill R: Tumor suppressor loci from the short arm of chromosome 3. Lung Cancer (supplement), Vol. 11, abstract 72, pg.19, 1994.
71. Gemmill RM, Chumakov I, Scott P, Rigault P, Cypser J, Chen Q, Weissenbach J, Gardiner K, Pekarski Y, Gall I Le, Guillom E Li, Robinson L, Hahner L, Todd S, Cohen D and **Drabkin HA**. An Integrated YAC Contig Map for Human Chromosome 3. Cold Spring Harbor Laboratory Symposium: Genome Mapping & Sequencing: pg. 72, 1994
72. Gemmill RM, Chumakov I, Scott P, Rigault P, Cypser J, Chen Q, Weissenbach J, Gardiner K, Pekarski Y, Gall I Le, Guillom E Li, Robinson L, Hahner L, Todd S, Cohen D and

- Drabkin HA.** An Integrated YAC Contig Map for Human Chromosome 3. 44th Annual Meeting of the American Society of Human Genetics, Montreal, Quebec, October 18-22, 1994; Am J Hum Genet 55S:A258, 1994.
73. Patterson D, Graw S, Gardiner K, **Drabkin H**, Donaldson D, Hall-Johnson K and Berger R. Integration and Validation of the Physical Map of Chromosome 21 Using a High Resolution Hybrid Panel, STS Mapping and Rare Cleavage. Cold Spring Harbor Laboratory Symposium: Genome Mapping & Sequencing: pg. 214, 1994
 74. Daly MC, Xiang RH, Carlson HC, Killary AM, Buys CH, **Drabkin H** and Naylor SL. Characterization of a candidate tumor suppressor gene on chromosome 3. Am. J. Hum Gen (Suppl) abstract 87, 1994.
 75. Gemmill R, Roche J, Todd S, Franklin W, Boldog F, Swanton M, Naylor S, Kok K, Buys C and **Drabkin H**: Analysis of 3p tumor suppressor loci in human lung cancer. Presented: Cold Spring Harbor, October, 1994.
 76. Todd S, Gemmill R, **Drabkin H** and Franklin W: Loss of heterozygosity in the short arm of chromosome 3p in small cell lung carcinoma (SCLC) and squamous dysplasia (SD) of bronchial mucosa. AACR, October, 1994.
 77. Todd S, Franklin WA, Weissenbach J, **Drabkin H**, Gemmill RM: Proximal chromosome 3p harbors a DNA segment frequently deleted in small cell lung cancer. 44th Annual Meeting of the American Society of Human Genetics, Montreal, Quebec, October 18-22, 1994, Am J Hum Genet 55S:A72, 1994.
 78. Varella-Garcia M, Tajara EH, Ortiz L, **Drabkin HA**, Gemmill RM: Chromosome 3 instability in human small-cell lung cancer cell lines and its role in the detection of deletional events by FISH techniques. 11#161# Congreso Latinoamericano de Genetica. Puerto Jalisco, Jalisco, Mexico, September 25-30, pp. 158, 1994.
 79. Erickson, P., Robinson, M. and **Drabkin, H.A.** Nuclear localization of the t(8;21) AML protein, AML1/ETO, in cells having cytoplasmic AML1. Journal of Cellular Biochemistry, Supp 19A, A1-318, 1995
 80. Varella-Garcia M, Suijkerbuijk RF, **Drabkin HA**, Gemmill RM: Detection of deletional events in lung cancer by FISH. 6th International Workshop on Chromosomes in Solid Tumors. Tucson AZ, February 19-21, 1995.
 81. E. Li, B. Waggoner, J. Cypser, H. Wang, **H. Drabkin** and R. Gemmill. Use of reciprocal cosmid-cdna library screening to identify and map ests from human chromosome 3. Presented at the Transcribed Sequences Workshop, Marseille, France, Nov. 5-8, 1995.

82. Naylor SL, Hensel CH, Xiang RH, Daly MC, Garcia D, Buys CHCM, **Drabkin H**, Carlson H, Kok K, and Kerbacher K. Tumor suppression and the 21.3 region of chromosome 3. *Am. Journal of Hum Genet.* 57 (supp): A73, 1995
83. RM Gemmill, I Chumakov, P Scott, B Waggoner, P Rigault, J Cypser, Q Chen, J Weissenbach, K Gardiner, Y Pekarski, I Le Gall, S Guillon, E Li, L Robinson, L Hahner, S Todd, D Cohen and **HA Drabkin**. An Integrated Yac Contig Map for Human Chromosome 3. *Am. Journal of Hum Genet.* 57 (supp): A1504, 1995
84. **Drabkin H**, Boldog F, Robinson M, Roche J, Giardini K, Lundstrom R, Robinson L and Gemmill RM. A Recurrent Homozygously Deleted Region in Human Carcinoma Cells Affecting 3p14. *Proc. AACR 37*: pg. 127 #3515, 1996 .
85. Varella-Garcia M., Franklin W., Folkvord J., **Drabkin H.A**, Pan X., Archer P., Gemmill R.G. Detection of chromosome 3 abnormalities in lung tumor specimens by fluorescence in situ hybridization (FISH). *Proc. AACR 37*: pg. 127 #876, 1996
86. Franklin WA, Todd S, Gemmill R, **Drabkin H**, Cook R, Sorenson J, Folkvord J, Haney J, Low R, Proudfoot S, Kennedy T and Miller Y. Correlative assessment of morphologic, immunophenotypic and genetic changes in bronchial epithelium of tobacco smokers. *Chest*: 109, p.26S, 1996
87. Franklin WA, Folkvord J, Johnson G, Gemmill RM, **Drabkin H**, Dessev G, Qian N, Miller Y, Varella-Garcia M, Anderson S. Transfection of Bronchial Epithelial Cells (BE) from Dysplastic Sites with SV40 T Antigen and v-src. presented, AACR 1996
88. Varella-Garcia M, Franklin W, Folkvord J, Archer P, Pan Z, **Drabkin H** and Gemmill R. Detection of Chromosome 3 Abnormalities in Cytospin and Touch Preparations of Lung Tumors Using in situ Fluorescence Hybridization. Presented-Fifth European Workshop on Cytogenetics and Molecular Genetics of Solid Tumors.
89. Varella-Garcia M, Rabenhorst SH, Franklin W, Archer P, Gemmill RM and **Drabkin HA**. Fluorescence in situ Hybridization Markers for 3p Deletion in Lung Cancer. *International Congress in Human Genetics.* Rio de Janerio, Brazil, 1996
90. **H. Drabkin** F. Boldog, J. Roche, M. Robinson, L. Robinson W. Franklin, H. Klinger and R. Gemmill. Homozygous deletions affecting 3p14.2 in human carcinoma cell lines: A case of genomic instability? *Cancer Genetics & Tumor Suppressor Genes.* CSH Meeting, Aug 8-14, 1996.
91. **H. Drabkin**, M Robinson, R Lundstrom, J Cypser, E Li and R Gemmill. Chromosome 3 beyond the physical map. *Brazilian Journal of Genetics* 19, No 2 Supp. #158, pg. 131, 1996 (9th International Congress of Human Genetics).

92. F. Boldog, R. Gemmill, J. West, M. Robinson, L. Robinson, E. Li, J. Roche, S. Todd, J. Jacobsen, H. Klinger and **H. Drabkin**. 3p14 Homozygous Deletions in Carcinomas of Lung, Breast, Colon and Cervix and Sequence Analysis of FRA3B. 8th World Conference on Lung Cancer. Lung Cancer 18: 141, 1997.
93. M Varella-Garcia, K Rao, SH Rabenhorst JS Weist, **H Drabkin**, R Gemmill, MW Anderson and WA Franklin. Complex abnormalities involving regions 3p and 9p in non-small cell lung cancer (NSCLC) revealed bu fluorescence in situ hybridization (FISH). Lung Cancer 18: 140, 1997.
94. WA Franklin, JM Folkvord, TC Kennedy, J Dempsey, YE Miller, **H Drabkin**, ML Varella-Garcia and SM Anderson. Expansion of bronchial epithelial cell populations from bronchoscopic biopsies and thoracotomy specimens by a one step transfection of cultured cells with SV-40 T antigen. Lung Cancer 18: 14153, 1997.
95. Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Hilliker CE, Hahner L, Anderson M, Weist JS, **Drabkin HA** and Gemmill RM. Homozygous deletions of human chromosome 3p in lung tumors. Lung Cancer 18: 14157, 1997.
96. SH Rabenhorst, Rao KP, WA Franklin, **HA Drabkin**, RM Gemmill and M. Varella-Garcia. Chromosome 3 in Lung Tumors Abnormalities Detected by Fluorescent in situ Hybridization. Seventh International Workshop on Chromosomes in Solid Tumors, Jan 20-22, 1977, Tucson, AZ.
97. W. Franklin, M. Varella-Garcia, KP Rao, RM Gemmill, **H. Drabkin** et al. Multiparametric analysis of pre-invasive bronchial epithelium in high risk patients. Presented. SPORE Workshop. Washington, DC July 1997.
98. G. Paskulin, G Philips, R Morgan, A Sandberg, K Richkind, CL Borovik, L McGavran, N Rabinovich, J Dietz-Band, P Erickson, **HA. Drabkin** & M Varella-Garcia. Development of t(8;21) Fish Reagents for Monitoring Minimal Residual Disease (MRD). Presented - 1st meeting on Acute Leukemias with structurally altered core binding factor subunits, Erasmus University, Rotterdam, The Netherlands. June 27-29, 1997.
99. H. Poirel, M. Mauchauffe, V Lacronique, J Hgysdael, P Erickson, **H Drabkin**, R Berger and O Bernard. Etude de l'expression des produits du gene TEL/ETV6 normaux et anormaux des leucemies humaines. 4eme Congres annuel du CHO; pg 63; Ligue Nationale Contre Le Cancer. Oct. 19-22, 1997.
100. Franklin W, Keith RL, Varella-Garcia M, Gemmill RM, **Drabkin H**, Haney J, Fox K, Anderson MW, Wiest JS, Otstott J, Prindeville S, Byers T, Kennedy T & Miller Y. Molecular Abnormalities and micropapillary histologic lesions in bronchial epithelium of smokers at risk for lung cancer. Proc. of the AACR 39: pg 125 (#850),1998.

101. Varella-Garcia M, Gemmill R, **Drabkin H**, Lotto A and Franklin WA. Correlation of allelic loss at chromosome 3p14.2 and 3p21.3.31 detected by PCR for microsatellite repeats with FISH suggests that allelic loss often precedes chromosomal duplication in non-small cell lung carcinomas (NSCLC). AACR 39: pg 235 (#1604),1998.
102. RM Gemmill, JD West, F Boldog, N Tanaka, LJ Robinson, DI Smith, F Li and **HA Drabkin** (1998). The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a novel *patched* related gene, TRC8. presented: Cold Spring Harbor, Pathways to Cancer March 11-14, 1998.
103. M. Varella-Garcia, J. Murata-Collins, R. Berger, M. Andreef, Hong Ai, K. Richkind, L. McGavran, G. Paskulin, P. Erickson, and **H. Drabkin**. Detection of minimal residual disease in t(8;21) acute myelogenous leukemia (AML) using a d-fish aml1/eto probe. abstr. # 303. Am. Soc. Hematology Dec. 4-8, 1998.
104. Brambilla, E., Hu, L., **Drabkin, H.**, Roche, J. Differential protein localization of Semaphorin IV in normal lung and lung carcinomas. 88th Annual Meeting of the United States and Canadian Academy of Pathology (USCAP), San Francisco, March 20-26 , 1999.
105. Brizard, F., Morel, F., Lacotte, L., Varella-Garcia, M., Roche, J., **Drabkin, H.** and Brizard, A. Réarrangements AML1/ETO et PML/RARA dans un cas de LAM2 avec translocation t(15;17)(q22;q12). Hématologie, 1999.
106. Roche J., Constantin B., Brambilla E. and **Drabkin H**. Semaphorin IV localization in human malignant lung and dividing cells : a suggested role in cell migration. presented: P-395, European Society of Human Genetics, Geneva Switzerland, 5/26-6/1, 1999.
107. Franklin W, Berezuk M, Gemmill RM, **Drabkin H**, Murphy J and Varella-Garcia M. Small and Large Scale Genetic Abnormalities in Lung Carcinogenesis: LOH and Chromosomal Instability. Presented, IASLC 1999.
108. West, J., Calvo, R., Winn, R., Franklin, W.A., Gemmill, R.M. and **H.A. Drabkin**. Dysregulation of the WNT, HOX and FGF Gene Families in Lung Tumors. Presented, IASLC Workshop, Aspen, CO, Aug., 1999.
109. J. Roche, E. Brambilla, **H. Drabkin**, and B. Constantin. Semaphorin Sema3F Localization In Malignant Human Lung And Cell Lines : A Suggested Role In Cell Adhesion And Cell Migration. ASCO 1999.
110. **Drabkin HA**. The Hereditary Renal/Thyroid Cancer 3;8 TRanslocation Disrupts TRC8, a Gene with Partial Similarity to Patched. Invited Lecture, Johannes-Gutenberg University Mainz, Germany, March 31, 2000.
111. R. Calvo, J. West, W. Franklin, P. Erickson, L. Bemis, E. Li, B. Helfrich, P. Bunn, J. Roche, E. Brambilla, R. Rosell, R. M. Gemmill and **H. A. Drabkin**. HOX Gene Expression in

- Human Lung Cancer. Presented, SPORE Investigator's Meeting, Washington, DC, July 2000.
112. Calvo R. and **Drabkin H.** Embryonic Genes in Cancer. European Society for Medical Oncology. presented: ESMO International Conference, Hamburg, Germany, Oct. 13-17, 2000.
 113. RM Gemmill, L Bemis, J Lee, P Erickson, J Hooper and **HA Drabkin.** The Hereditary Kidney Cancer TRC8 Gene Functions in Parallel with VHL and Affects *Drosophila* Development. presented 4th Workshop on Proteasomes. Clermon-Ferrand, France April 4-7, 2001.
 114. RM Bremnes, L Bemis, R Veve, E Gabrielson, K Ferguson, P Erickson, FR Hirsch, RM Gemmill, WA Franklin and **HA Drabkin.** Prognostic Role of E-cadherin in Non-Small Cell Lung Cancer (NSCLC) Utilizing High Throughput Tissue Microarrays and its Regulation by the WNT Pathway. Presented, SPORE Workshop, Wshington, DC, July 2001
 115. L Bemis, P Erickson, WA. Franklin, R Bremnes, E Brambilla, K Ferguson, A Baron, C Zeng, RM. Gemmill1 and **HA. Drabkin.** Analysis of regulatory interactions controlling E-cadherin expression and its up-regulation in lung cancers. Keystone WNT Pathway Symposium, Taos NM, (2002).
 116. RM Gemmill, D Chamovitz, D Segal, Ti Hsu, M Grant, S B, J E. Hooper and **HA Drabkin.** Genetic Analysis of Growth Suppression Induced by the t(3;8) Hereditary Renal Cancer Gene TRC8. AACR 2003.
 117. T Ohira, RM Gemmill, L Bemis, P Erickson, K Ferguson, S Kusy, J Roche, E Brambilla, C Zeng, A Baron, E Wilder, A Rustgi, J Kitajewski, E Gabrielson, R Bremnes, W Franklin and **HA Drabkin** (2002). Reversal of E-cadherin Loss in Lung Cancer. Presented at the International Proteasome Symposium, Clermont-Ferrand, France, April 27-29, 2003.
 118. J Roche, C Zeng, A Baron, S Gadgil, RM Gemmill, I Tigaud, X Thomas and **HA Drabkin** (2003). HOX Expression in AML Identifies A Distinct Subset Of Patients With Intermediate Cytogenetics. ASH 2003.
 119. SE Witta, B Helfrich, M Sugita, FR Hirsch, W Franklin, RM Gemmill, **HA Drabkin** and PA Bunn. Expression of the E-cadherin inhibitory zinc finger transcription factors dEF1/ZEB1 and SIP1/ZEB2 correlates with resistance to EGFR inhibitors. AACR 2004.
 120. RM Gemmill, J Lee, D Chamovitz, D Segal, S Lempka S Britt, JE Hooper and **HA Drabkin.** Growth Suppression Induced by the t(3;8) Hereditary Renal Cancer Trc8 Gene Is Dependent Upon Jab1/Csn5. ZOMES III - COP9 signalosome, Proteasome and eIF3: at the interface between signaling & proteolysis, Berlin, Germany. May 9-12, 2004.

121. Kusy S, Nasarre P, Chan D, Potiron V, **Drabkin H** et Roche J. Rôle anti-tumoral de la sémaphorine SEMA3F, Euro-Cancer Conference, 2004.
122. Kusy S, Nasarre P¹, Chan D, Potiron V, Bunn P, Gemmill, R, **Drabkin H** & Roche J. Inhibition of Lung Cancer Tumorigenesis by SEMA3F. Annual NCI SPORE Workshop, 2004.
123. SE Witta, R Lapadat, C Coldren, M Geraci, M Sugita, B Helfrich, AE Barón, C Zeng, M Varella-Garcia, RM Gemmill, **HA Drabkin**, W Franklin, FR Hirsch, JD Minna, PA. Bunn. Genes and Protein Involved in Predicting Sensitivity / Resistance to Gefitinib in Human Lung Cancer Cell Lines. Annual NCI SPORE Workshop, 2004.
124. Homeodomain Expression in AML and T-ALL Cell Lines. S Gadgil, X Ying SU, C Zeng, A Barón, O Bernard and **H Drabkin**. Abstract #639, Molecular Biology and Pathophysiology of AML, Am. Soc. Hematology (ASH), San Diego, CA Dec 4-7, 2004.
125. M Dohadwala, SC Yang, J Luo, S Sharma, RK Batra, M Huang, Y Lin, L Goodglick, K Krysan, MC Fishbein, L Hong, R Cameron, RM Gemmill, **HA Drabkin** and SM Dubinett (2005). AACR Annual meeting, April 16-20, Abstract # 246.
126. Potiron V, Kusy S, Nasarre P, Chan D, Constantin B, Gemmill R, **Drabkin H** & Roche J. Semaphorin 3f has anti-tumor activity in the lung. AACR Annual meeting, April 16-20, Abstract # 2898.
127. **HA Drabkin** & RM Gemmill (2005). Synergistic Growth Inhibition by Iressa and Rapamycin in Renal Cell Carcinoma with wild-type VHL. AACR Annual meeting, April 16-20, Abstract # 3406.
128. RM Gemmill, J Lee, D Chamovitz, D Segal, JE Hooper and **HA Drabkin** (2005). Growth Suppression Induced by the TRC8 Hereditary Renal Cell Cancer Gene is Dependent upon JAB1/CSN5. AACR Annual meeting, April 16-20, Abstract # 5562.
129. J Mouchawar, JL Hopper, MC Southey, C Korch, **H Drabkin**, M Stopponi, T Byers, M. R.E. McCredie, GG. Giles (2005). Population-based estimate of the contribution of TP53 mutations to early-onset breast cancer: Preliminary Results from the Breast Cancer Family Registry. submitted AACR.
130. Christopher W. Ryan, Bryan H. Goldman, Primo N. Lara, Jr., Tomasz M. Beer, **Harry A. Drabkin**, Derek Raghavan, E. David Crawford (2006). Sorafenib plus interferon- α 2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. presented ASCO 2006.
131. R. Bukowski, D. McDermott, F. Kabbinavar, R. Figlin, K. Flaherty, S. Srinivas, U. Vaishampayan, **H. Drabkin**, J. Dutcher, F. Scappaticci (2006). Phase 2 Study of Erlotinib

- (E) plus Bevacizumab (B) vs B Alone in Metastatic Renal Cell Carcinoma (RCC). presented ASCO 2006.
132. LJ Costa, M Gonzalez, K Breaker, K Ellis, F Crighton, F Kim & **HA Drabkin**. Sunitinib malate has activity in advanced RCC previously treated with sorafenib. Kidney Cancer Association Symposium, Chicago, IL Sept. 2006.
 133. **H. Drabkin**, R. A. Figlin, W. M. Stadler, T.E. Hutson, J. Hajdenberg, L. Chu, D. Trent, L. Campos, F. Kelly, and R. Bukowski, on behalf of the ARCCS Investigators The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in prior bevacizumab patients (pts). Submitted – ASCO, 2007
 134. Bryan H. Goldman, Primo N. Lara, Jr., Tomasz M. Beer, **Harry A. Drabkin**, Philip C. Mack, E. David Crawford, Christopher W. Ryan. Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): an analysis of SWOG 0412. Submitted – ASCO, 2007.
 135. Potiron V, Nasarre P, Clarhaut J, Augustin H, Gemmill R, Roche J & **Drabkin H**. Presented, 10th Colloquium of the French Angiogenesis Network, March 29-30, 2007, Paris, France. La Sémaphorine SEMA3F réduit l'expression du VEGF et l'angiogenèse induite par les lignées tumorales bronchiques H157 et H460. Potiron V, Nasarre P, Clarhaut J, Augustin H, Gemmill R, Roche J et **Drabkin H** (2007). La sémaphorine SEMA3F réduit l'expression du VEGF et l'angiogenèse chez des lignées tumorales bronchiques. Presented - Eurocancer à Paris, June 26, 2007.
 136. J. J. Knox, R. A. Figlin, W. M. Stadler, C.A. Henderson, **H.A. Drabkin**, D. F. McDermott, N. Gabrail, W. H. Miller, J. Hainsworth, C. W. Ryan, L. Cupit, C. Xia, R. M. Bukowski, on behalf of the ARCCS Investigators. Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. For presentation, 1st European Multidisciplinary Meeting on Urological Cancers.
 137. Luciano Costa, Girish Sharma, Robert Gemmill & **Harry Drabkin** (2008). Combined sorafenib plus vorinostat causes synergistic growth inhibition in kidney cancer cells. Abstract # 402, ASCO GU Cancers Symposium. San Francisco, Feb. 14-16, 2008.
 138. Potiron V, Nasarre P, Sharma G, Gemmill R, Roche J and **Drabkin H**. Regulation of tumor angiogenesis by semaphorin SEMA3F. EMBO Workshop: Semaphorin Function and Mechanisms of Action May 8 - 11, 2008 Abbaye des Vaulx de Cernay, France.
 139. Sharma G, Costa L, Gadgil S, Decess I, Starkova J, Gemmill R, **Drabkin H**. Synergistic growth inhibitory effects of sorafenib and vorinostat against human kidney and lung cancer cells [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract nr 729.

140. Joëlle Roche, Jonathan Clarhaut, Robert M. Gemmill, Slimane Ait-Si-Ali, Jean Imbert and **Harry A. Drabkin**. ZEB-1 can repress SEMA3F Semaphorin, a tumor suppressor gene in lung cancer. Oral Presentation. EUROCANCER, PALAIS DES CONGRES, Paris, France, June 24-26, 2008. Received “first prize” for basic research.
141. F. Cappuzzo, M. Varella-Garcia, S. Gajapathy, E. Rossi, **H. Drabkin**, R. Gemmill, Rozzano. MYC And EIF3h co-amplification Significantly Improve Response And Survival of Non-Small Cell Lung Cancer Patients (NSCLC) Treated With Gefitinib. Accepted - ESMO 2008.
142. G Sharma, LJ Costa, C Korch, RM Gemmill and **HA Drabkin** (2009). Synergistic Growth Inhibition of RCC and NSCLC Cell Lines by Sorafenib plus Vorinostat and Induction of Angiogenic Genes by ER Stress - *accepted* AACR annual meeting
143. M Mitas, D Timmons, D Rimm, L Tanoue, A Khor, G Silvestri, C Reed, C Knaak, C Smith, E Garrett-Mayers, M Wallace, **HA Drabkin** and R Gemmill (2009). Prognosis-driven drug discovery in NSCLC adenocarcinoma: High throughput screening for compounds that inhibit the epithelial-to-mesenchymal inducer Zeb1, or the metastases-inducer AGR2 - *submitted* late-breaking news, AACR

C. Research Support

P50CA 058187 (SPORE: Bunn-PI; Component: Gemmill-PI, Drabkin-CoPI)
 NIH 05/01/08-04/30/09
 SPORE in Lung Cancer

SPORE (Pre-Award) (Drabkin)
 NIH/NCI 05/01/08-04/04/13

2P50CA 058187 (SPORE: Bunn-PI; Component: Gemmill-PI, Drabkin-CoPI)
 NIH 05/01/03-04/30/08
 SPORE in Lung Cancer

1P30 CA46934-09 (Bunn) 02/01/06-01/03/12
 National Cancer Institute
 DNA Sequencing Core Director

1R01 CA76035-01 A1 (Drabkin) 05/01/03-04/30/07
NIH
Molecular-Genetic Analysis of 3p14 Genomic Stability

R33 CA097710 (Drabkin)
NIH/NCI 09/01/02-08/31/06
Quantitative HOX Expression as a Prognostic Marker in AML

INDUSTRY SUPPORTED CLINICAL STUDIES IN METASTATIC RCC:

- Bay43-9006 vs placebo (2004-present)
- Bay43-9006 expanded access (2005)
- Pfizer SU011248 vs IFN (2004-present)
- Genentech Avastin vs Avastin + Tarceva (completed 2004)
- Argos 2006-present (autologous tumor vaccine)
- GSK GW786034 2006-present
- Rapamycin plus Tarceva 2006-present (Investigator-initiated, Genentech-sponsored)
- Double-Blind Randomized Placebo-Controlled Phase III Study to Assess Efficacy of recMAGE-A3 + AS15 Antigen-specific Cancer Immunotherapeutic as Adjuvant Therapy
- Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin)
- Phase II, Open Label, Single Arm Study of AS1411 in Pts with Metastatic RCC
- Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in RCC
-

CLINICAL / TEACHING ACTIVITIES:

1. Director, Metastatic Renal Cell Carcinoma Clinic (weekly).
2. Inpatient Attending Malignant Hematology / Oncology Services (1 month/year). Daily teaching with Fellows, Residents and Interns covering basic and subspecialty patient care, pathogenesis of disease and newer therapies.
3. Supervision and teaching of Laboratory Fellows and Post-doctoral Fellows (daily).
4. Oncology Division Conference Series (two hrs weekly).
5. Lecturer, Molecular Biology of Cancer Seminar Series.
6. Cell Therapeutics Journal Club (1 hr weekly)

GRADUATE STUDENTS:

1. Jason Lee, 2000-present, project “TRC8”, Human Medical Genetics Program
2. Sophie Kusy, April-August 2003, project “Semaphorin 3F”, training with Professeur Joëlle Roche at the Université de Poitiers
3. Vincent Potiron, Oct. 2003 - 2005. M. Potiron will obtain his Ph.D. from the Université de Poitiers under the Directorship of Professeur Joëlle Roche and co-Directorship of Dr. Drabkin. The majority of the laboratory experience was performed in Dr. Drabkin’s lab.

CLINICAL ONCOLOGY FELLOWS:

1. Stuart Gold, Ph.D., project “Chr.3p Alterations and Cancer”, currently at University of North Carolina, Chapel Hill
2. Marie Wood, M.D., 1988-1990, project “Chr.3p Alterations and Cancer”, currently University of Vermont.
3. George Phillips, M.D., 1993-1995, project “Development of t(8;21) FISH Probes”, currently at University of Vermont
4. Bruno Madeiros, M.D. – July 2003-2005
5. Luciano Costa, M.D., Dec. 2004-2006
6. Munira Shabbir, MD.,
7. Jimmy Wells, MD

POST-DOCTORAL FELLOWS:

1. Gail Harrison, Ph.D., 1985-1987, project “Genes and Cancer”, currently Associate Professor, University of Colorado Health Sciences Center
2. Marshall Swanton, Ph.D., 1992-1994, project “Genes and Cancer”, currently Private Business
3. Ethan Whisenant, Ph.D., project “Chromosome Mapping”, currently US Patent Office

4. Joelle Roche, Ph.D., 1985-1987, project “Physical Map”, currently Professeur, Universite du Poitiers, Poitiers, France
5. Tatsuo Ohira, M.D., Ph.D., 2001-2003, project “E Cadherin”, returning to Tokyo Medical University

Co-Mentored with Robert M. Gemmill, Ph.D.:

6. James West, Ph.D., 1996-1999, project “TRC8 protein expression”, currently Instructor, Pulmonary Sciences, UCHSC
7. Roser Calvo, Ph.D., 1998-1999, project “HOX loci in cancer”, currently University of Barcelona
8. Naotake Tanaka, M.D., Ph.D., 1997-1998, project “Developmental pathways in cancer”, currently Chiba University, Japan
9. Masatsugu Ueda, M.D., 1998-1999, project “Beta catenin mutations in uterine/cervical cancer”, currently Osaka Medical College, Japan
10. Robert Winn, M.D., 1998-1999, project “WNT gene expression in lung cancer”, currently Assistant Professor, Pulmonary Sciences, UCHSC
11. Julia Starkova, PhD., 2006-2008, project “Hox genes in leukemogenesis”, returning to Kosice, The Slovak Republic

SUMMER CANCER FELLOWSHIP STUDENTS:

1. Charles Bennet - June-July 1996
2. Meghan Treitz - June-July 1996
3. David Martinez, 1999 (returned 2005 for one month before med. School)
4. Emily Freed, 2000
5. Scott Lempka, 2001
6. Preetaj Grewal 2001
7. Scott Lempka, 2002
8. Toby Hays 2002
9. Amy Liu – 2003
10. Jessica Zinck – 2007
11. Robert Glass – 2008
12. Joseph Alge - 2008

